{"title":"Predictors of botulinum toxin type A response in patients with migraine: a meta-analysis.","authors":"Shaoqi Wu, Chang Zhou","doi":"10.1080/01616412.2025.2541293","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Migraine is one of the most common neurological diseases, imposing a heavy burden on society. Botulinum toxin type A (BT-A) has been approved as a safe and effective preventive treatment; however, not all patients report effectiveness after BT-A treatment. Thus, identifying BT-A responders in advance is valuable for treatment. Several studies have shown that some characteristics of headache, like a shorter disease duration and the absence of medication overuse, are potential predictors of clinical response. This meta-analysis aims to identify predictors linked to BT-A in people with migraine.</p><p><strong>Methods: </strong>PubMed, Web of Science, Embase and the Cochrane Library were searched for studies. All cohort studies reporting the factors of responders and non-responders to BT-A injection were selected.</p><p><strong>Results: </strong>Eleven studies met the criteria for selection. Of the 18 factors identified, only six were reported in at least three studies. BT-A response was associated with disease duration (MD: -2.37, CI: [-4.03, -0.83], <i>p</i> = 0.0002). In sensitivity analysis, the outcome of headache days was also statistically significant (MD: 1.02, CI: [0.45, 1.59], <i>p</i> = 0.0004).</p><p><strong>Conclusion: </strong>The findings of this meta-analysis support disease duration and headache days as predictive factors of BT-A response in people with migraine. Injecting BT-A at an early stage might be beneficial for migraine patients. However, the predictors were based on a small number of studies; thus, more studies are needed to prove the outcome. Several other factors may be associated with the response to BT-A but reported in a few studies. Therefore, more studies are needed to evaluate additional predictors.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-15"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01616412.2025.2541293","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Migraine is one of the most common neurological diseases, imposing a heavy burden on society. Botulinum toxin type A (BT-A) has been approved as a safe and effective preventive treatment; however, not all patients report effectiveness after BT-A treatment. Thus, identifying BT-A responders in advance is valuable for treatment. Several studies have shown that some characteristics of headache, like a shorter disease duration and the absence of medication overuse, are potential predictors of clinical response. This meta-analysis aims to identify predictors linked to BT-A in people with migraine.
Methods: PubMed, Web of Science, Embase and the Cochrane Library were searched for studies. All cohort studies reporting the factors of responders and non-responders to BT-A injection were selected.
Results: Eleven studies met the criteria for selection. Of the 18 factors identified, only six were reported in at least three studies. BT-A response was associated with disease duration (MD: -2.37, CI: [-4.03, -0.83], p = 0.0002). In sensitivity analysis, the outcome of headache days was also statistically significant (MD: 1.02, CI: [0.45, 1.59], p = 0.0004).
Conclusion: The findings of this meta-analysis support disease duration and headache days as predictive factors of BT-A response in people with migraine. Injecting BT-A at an early stage might be beneficial for migraine patients. However, the predictors were based on a small number of studies; thus, more studies are needed to prove the outcome. Several other factors may be associated with the response to BT-A but reported in a few studies. Therefore, more studies are needed to evaluate additional predictors.
期刊介绍:
Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences. It provides a medium for those who recognize the wider implications of their work and who wish to be informed of the relevant experience of others in related and more distant fields.
The scope of the journal includes:
•Stem cell applications
•Molecular neuroscience
•Neuropharmacology
•Neuroradiology
•Neurochemistry
•Biomathematical models
•Endovascular neurosurgery
•Innovation in neurosurgery.